---
title: Detect freezing through oculomotor markers
nct_id: NCT06663826
status: RECRUITING
sponsor: machineMD AG
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06663826"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06663826"
last_fetched: "2026-05-10T14:08:07.516Z"
source: "Parkinson's Pathways (curated)"
---
# Detect freezing through oculomotor markers

**Goal (in five words):** Detect freezing through oculomotor markers

**Official Title:** Development of Digital Diagnostic Devices for Parkinson's Disease

**Trial ID:** [NCT06663826](https://clinicaltrials.gov/study/NCT06663826)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** machineMD AG
- **Target Enrollment:** 100 participants
- **Start Date:** 2024-10-01
- **Completion Date:** 2026-06-30
- **Conditions:** Parkinson Disease
- **Interventions:** oculomotor and pupillary function assessment
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

They want to see whether digital measurements of eye movements and pupil reactions can reveal brain changes linked to walking problems in Parkinson's, especially daily freezing or festination. The study uses oculomotor and pupillary assessments recorded by digital devices, potentially at home over WiFi, to capture objective markers of balance and gait while allowing regular Parkinson's medications but excluding drugs that blunt eye responses. Looking for people with Parkinson's or atypical parkinsonism who can report daily freezing or festination, have a refractive error between -6 and +4 diopters, can walk unsupported or with an aid for at least five minutes, and who do not have other neurological diseases, eye or skin issues that affect measurements, interfering medications, severe cognitive problems, or poor home WiFi.

## Eligibility

- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of Parkinson's disease or of another parkinsonian syndrome (atypical Parkinson's)
* Refractive error between -6 and +4 diopters, on both eyes
* Informed consent by participant documented per signature
* Able to self-report history of daily gait freezing and/or festination
* Able to walk unsupported or using an aid for at least 5 minutes and if over 69 used to carrying out this level of exercise

Exclusion Criteria:

* Other known neurological diseases
* Current medication/drugs that could potentially influence performance in ocular motor tasks and/or compliance in the judgement of the investigator (e.g. benzodiazepines, alcohol, stimulants, or recreational drugs) - except Parkinson's medications
* Incapacity to understand and comply with the examination (e.g. due to advanced cognitive decline, failure to comply with easy experimental instructions and tasks)
* Any injury or disorder that may affect eye movement measurements or balance (other than Parkinson's or referring primary condition)
* Any skin conditions or broken skin in the calf and behind the knee area
* Lack of access or limited connectivity to WiFi in home setting
```

## Locations (1)

- University Hospital of Zurich, Zurich, Canton of Zurich, Switzerland _(47.3667, 8.5500)_
  - Konrad Weber, Prof. Dr. med. — (CONTACT) — +41 44 255 55 49 — Konrad.Weber@usz.ch
  - Erika Han, MD — (CONTACT) — erika.han@usz.ch
  - Konrad Weber, Prof. Dr. med. — (PRINCIPAL_INVESTIGATOR)
  - Erika Han, MD — (SUB_INVESTIGATOR)

## Central Contacts

- Ana Coito, Ph.D. — (CONTACT) — +41 (0)31 589 67 92 — ana.coito@machinemd.com
- Pia Massatsch, Ph.D. — (CONTACT) — pia.massatsch@machinemd.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06663826*  
*HTML version: https://parkinsonspathways.com/trial/NCT06663826*  
*Source data: https://clinicaltrials.gov/study/NCT06663826*